D. Boral Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at D. Boral Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $18.00 price target on the stock. D. Boral Capital's target price points to a potential upside of 169.46% from the stock's previous close.

Separately, Chardan Capital reissued a "buy" rating and set a $14.00 price objective on shares of Coya Therapeutics in a report on Thursday, February 6th.

Coya Therapeutics Stock Performance

Shares of COYA stock traded up $0.21 during mid-day trading on Tuesday, hitting $6.68. The company's stock had a trading volume of 49,741 shares, compared to its average volume of 71,330. The company's fifty day simple moving average is $6.33 and its 200-day simple moving average is $6.49. Coya Therapeutics has a 52 week low of $4.75 and a 52 week high of $10.24. The company has a market cap of $111.72 million, a PE ratio of -10.28 and a beta of 0.31.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.14. The business had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.10 million. On average, equities analysts anticipate that Coya Therapeutics will post -1.15 earnings per share for the current year.

Remove Ads

Institutional Investors Weigh In On Coya Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in COYA. Northern Trust Corp raised its position in Coya Therapeutics by 12.2% during the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company's stock valued at $164,000 after purchasing an additional 3,099 shares in the last quarter. Geode Capital Management LLC raised its position in Coya Therapeutics by 3.3% during the third quarter. Geode Capital Management LLC now owns 142,309 shares of the company's stock valued at $918,000 after purchasing an additional 4,485 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Coya Therapeutics by 1,005.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock valued at $30,000 after purchasing an additional 4,777 shares in the last quarter. XTX Topco Ltd purchased a new stake in Coya Therapeutics during the fourth quarter valued at about $59,000. Finally, Jane Street Group LLC purchased a new stake in Coya Therapeutics during the fourth quarter valued at about $74,000. Hedge funds and other institutional investors own 39.75% of the company's stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.